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“The knowledge that you have emerged wiser and stronger from setbacks means that 
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Emerging micropollutants are chemical substances present in different matrices at 
very low concentrations, ranging from nanograms to micrograms per liter. Non-Steroidal 
Anti-Inflammatory Drugs (NSAID) are some of the most prescribed drugs worldwide and 
several studies report the presence of these substances in various hydric media including 
drinking water, surface water, and sewage water, among others. Since they are present in 
very low concentrations, their identification, quantification and removal are not easy 
tasks.  
The main objective of this work is to gather some knowledge about the most recent 
analytical methodologies in the field, in order to start the evaluation of this environmental 
and health problem in the Bragança region. Therefore, this work is based on the 
development of an analytical methodology to extract, detect and quantify non-steroidal 
anti-inflammatory drugs and on the validation of this methodology using real samples 
from different hydric media of the Bragança region.  
From an initial set of ten pharmaceutical drugs belonging to different 
pharmacological classes, a group of five NSAID, acetyl salicylic acid, diclofenac, 
ibuprofen, ketoprofen and naproxen, was selected as the prototype acidic molecules due 
to their relatively low pKa (3.49 to 4.91). After an extensive literature review, the solid 
phase extraction (SPE) was selected as extraction technique using an adsorbent 
(Chromabond® HLB) applicable for a wide range of analyte polarities. 
In order to improve the SPE recoveries, several experimental measurements were 
performed using different flow-rates for the adsorbent conditioning, sample loading, 
washing and elution steps. Extractions were performed with individual and mixture 
standards prepared in ultrapure water with the aim of evaluating the analytes recovery. 
The high performance liquid chromatography with photo diode array detector 
(HPLC-DAD) was the selected instrumental method of analysis with a Nucleosil C18 
column under reversed phase mode conditions. Several studies were carried out to 
optimize the mobile phase composition, mobile phase pH, elution flow-rate and 
wavelengths for detector monitorization. 
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After the optimization of some SPE/HPLC-DAD operating conditions, the 
developed methodology was validated analyzing six real samples collected from different 
aqueous sources in Bragança region: city tap water, well water, swimming pool, “river 
A” at two different points and “river B”. The river A, location 1, was contaminated with 
naproxen and ketoprofen and the well water sample indicated the presence of ketoprofen. 
For these samples, taking into account the limits of quantification (LOQ) of the 
developed analytical method, only river A contamination could be evaluated with a 
measured concentration of 11.230 ± 0.767 ppb for ketoprofen. The concentrations of 
naproxen in river A and ketoprofen in well water sample were below the LOQ but above 
the limit of detection (LOD), proving the presence of these compounds. 
Responses were also observed for acetyl salicylic acid in river A, location 1, and 
in pool water samples, but their values were below the LOD, therefore, it is not possible 
to confirm the presence of this NSAID in those samples. 
 
Keywords: Emerging Pollutants; Non-Steroidal Anti-Inflammatory Drugs; Hydric 
Media; Solid Phase Extraction, High Performance Liquid Chromatography - Diode Array 




Micropoluentes emergentes são substâncias químicas presentes em diferentes 
matrizes em concentrações muito baixas, variando de nanogramas a microgramas por 
litro. Os Anti-Inflamatórios Não-Esteróides são alguns dos fármacos mais prescritos em 
todo o mundo e diversos estudos reportam a presença destas substâncias em várias 
matrizes aquosas incluindo água potável, água superficial, águas residuais, entre outros. 
Como estão presentes em concentrações muito baixas, a sua identificação, quantificação 
e remoção não são tarefas fáceis. 
O principal objetivo deste trabalho é adquirir algum conhecimento sobre as mais 
recentes metodologias analíticas neste campo, a fim de iniciar a avaliação deste problema 
ambiental e de saúde na região de Bragança. Portanto, este trabalho é baseado no 
desenvolvimento de uma metodologia analítica para extrair, detetar e quantificar anti-
inflamatórios não-esteróides (AINEs) e na validação desta metodologia utilizando 
amostras reais de diferentes matrizes aquosas da região de Bragança.  
De um conjunto inicial de dez compostos pertencentes a diferentes classes 
farmacológicas, um grupo de cinco AINEs, ácido acetil salicílico, diclofenaco, 
ibuprofeno, cetoprofeno e naproxeno, foi selecionado, sendo constituído por moléculas 
protótipo de caráter ácido devido a seus valores relativamente baixos de pKa (3.49 a 4.91). 
Após uma extensa revisão bibliográfica, a Extração em Fase Sólida (EFS) foi a técnica 
selecionada utilizando um adsorvente (Chromabond® HLB) aplicável para uma vasta 
gama de polaridade dos analitos. 
Com o objetivo de aperfeiçoar as recuperações da EFS, várias medições 
experimentais foram realizadas usando diferentes caudais para as etapas de 
condicionamento do adsorvente, carregamento da amostra, limpeza e eluição. Foram 
feitas extrações dos compostos em padrões individuais e em misturas preparadas em água 
ultrapura a fim de avaliar a recuperação dos analitos. 
A cromatografia líquida de alta eficiência acoplada ao detetor de arranjo de díodos 
(CLAE-DAD) foi o método instrumental de análise selecionado, com uma coluna 
Nucleosil C18 sob condições de fase reversa. Diversos estudos foram feitos para otimizar 
 
vi 
a composição da fase móvel, o pH da fase móvel, o caudal de eluição e os comprimentos 
de onda monitorizados no detetor. 
Depois da otimização de algumas das condições de operação de EFS/CLAE-
DAD, a metodologia desenvolvida foi validada com a análise de seis amostras reais 
recolhidas em diferentes matrizes aquosas da região de Bragança: água de torneira da 
distribuição municipal, água de poço, água de piscina, “Rio A” em dois pontos distintos 
e “Rio B”. O Rio A, ponto 1, estava contaminado com naproxeno e cetoprofeno e a água 
de poço indicou a presença de cetoprofeno. 
Para estas amostras, considerando os limites de quantificação do método 
desenvolvido, apenas a contaminaçao do rio A pode ser avaliada com uma concentração 
medida de 11.230 ± 0.767 ppb para o cetoprofeno. As concentrações de naproxeno no rio 
A e de cetoprofeno na água de poço estavam abaixo do limite de quantificação, mas acima 
dos limites de deteção, provando a presença destes compostos. 
Houve também resposta para o ácido acetil salicílico no Rio A, ponto 1, e na água 
de piscina, mas seus valores estavam abaixo do LD, portanto, não se pode confirmar a 
presença destes AINEs nestas amostras. 
 
Palavras-chave: Poluentes emergentes; Anti-Inflamatórios Não-Esteróides; Matrizes 
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Due to the increasing anthropic action and industrial activities, the quality of water 
has been impaired and the contact and ingestion of contaminated water can cause 
injurious effects to living beings [1, 2]. 
Recently, some compounds that did not used to be found in the environment and 
were not considered as pollutants have been identified mainly in aqueous matrices, the 
so-called emerging pollutants. These are contaminants that can affect living beings and 
the environment but are not usually present in national or international environmental 
legislations. Such substances may be regulated in the future, if toxicity, health effects and 
bioaccumulation studies will stress this need [3]. Emerging micropollutants are some of 
these compounds that are found in very low concentrations ranging from nanograms to 
micrograms per liter. These substances, even in small quantities, may cause adverse 
reactions to living organisms with which they come into contact [4]. Different types of 
products can be sources of emerging micropollutants into the environment, including 
pharmaceuticals, cosmetics, synthetic hormones, surfactants, pesticides, cleaning 
products and others [5]. Medical drugs, in turn, can also be subdivided into different 
classes, such as analgesics and anti-inflammatories, antibiotics, antiepileptic, contrasting, 
synthetic steroids and others [6]. 
Pharmaceuticals are emerging micropollutants of significant relevance, since they 
normally have high pharmacological potency, which means that they can cause 
significant effects even at low concentrations. Furthermore, they are also designed to be 
persistent, keeping their chemical properties for long periods of time [7, 8]. As a result of 
being compounds found in low concentrations, the analysis and the study of drugs become 
challenging tasks. More sophisticated analysis methods are necessary to detect the 
substances in micro and nanograms amounts [4]. Thereby, it is recognized the demand to 
develop an effective method for quantifying, and consequently, monitoring drugs as 




1.2.1 Main objective  
The main objective of this work is to contribute to the development and validation 
of an experimental methodology that could be applied to the monitoring of emerging 
micropollutants in aqueous matrices of Bragança region. 
1.2.2 Specific objectives 
The analytical methodology development includes both solid phase extraction 
(SPE) technique and high performance liquid chromatography coupled with diode array 
detector (HPLC-DAD) main operation conditions optimization. 
For SPE, different flow-rates will be studied for all the main steps (conditioning, 
loading, washing and elution) in order to raise recoveries. 
The optimization of HPLC-DAD method will be performed by means of the 
selection of the most promising operating conditions to improve the compounds 
separation. Among these, the selection of the solvent composition, the solvent pH value, 
the mode of operation (isocratic or gradient) and the wavelength(s) for each analyte. 
The experimental methodology must be validated with the determination of the 
most relevant statistical parameters, such as, the calibration curves using a confidence 
level of 95%, the intermediate precision, the repeatability and the limits of quantification 
and detection. 
The developed methodology will be implemented by collecting and analyzing 




1.3 Report organization 
This master thesis report is organized in five main chapters. The first one presents 
a brief introduction to the relevance of the proposed work, the main objectives to be 
fulfilled and the organization of this report. 
In the second chapter it is presented an extensive state of the art, which includes 
some important definitions. The review of some recent published work, in the field of 
extraction techniques for the analysis of micropollutants and instrumental methods of 
analysis is also done. Besides, this introductory chapter will present the description of the 
most relevant equations and statistic parameters used for the experimental methodology 
validation. 
The third chapter is dedicated to list all the equipment, reagents and experimental 
procedures used in this work. In this chapter, it is presented the experimental work which 
is split in two main parts. The first one is dedicated to the development of the analytical 
methodology to extract and to quantify the selected anti-inflammatory drugs. The second 
one is directed to the implementation of the developed methodology using real aqueous 
samples from the Bragança region. 
In the fourth chapter, the main experimental results are presented and discussed. 
The fifth and final chapter gathers the main conclusions obtained in this work and 

























2. Literature review 
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2.1 Water and environment 
Water is an indispensable substance for human life, having applications ranging 
from its need for metabolic functions to its use for energy production [1, 2]. Nevertheless, 
in 2014 it was estimated that more than 700 million people had no access to potable water 
and, in the coming decades, the supply of this resource would be reduced to 75% of the 
currently available amount. It is estimated that, in each year, between 12500 to 15000 
km³ of water are used, and 4000 km³ are exclusively destined to industry, irrigation and 
domestic use. Furthermore, it is known that only 0.5% of the planet's water is freshwater 
available for consumption [9]. This information is even more alarming when considering 
the quality of water available for human consumption. It is known that with the increasing 
anthropic action and the industrial activities, the quality of this resource has been 
negatively affected [1]. 
2.1.1 Pollution in hydric media 
Population and urban growth are strongly associated with environmental 
degradation and increasing need for basic sanitation, waste treatment and access to 
drinking water. The response to this type of needs is not always achieved with the desired 
speed and efficacy, causing a high risk to the health of the population of regions without 
access to the types of treatments mentioned [10]. Contact and ingestion of contaminated 
water can cause harmful effects to living beings and are associated with most part of the 
diseases that affect the world population, especially parasitic diseases, such as 
schistosomiasis [9]. 
In addition to the water pollution caused by microbiological contamination, there 
are other factors, such as contamination by toxic metals, greatly emphasized between 
1970 and 1980. In the last decades, it was raised the interest about the presence of 
substances with less perceptible effects, and generally found in low concentrations, the 
recently called emerging pollutants [1]. 
2.2 Emerging pollutants 
With the recent advances in analytical techniques, new compounds can be 
identified in aqueous matrices [4]. The emerging pollutants are substances that have been 
detected in different environmental matrices and, until some time ago, were not 
considered as contaminants [5, 6]. These pollutants are present in the environment 
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worldwide and usually are sourced from domestic, commercial and industrial wastewater 
[11]. 
These contaminants may cause harm, but since their detection and quantification 
have only received some attention from the competent authorities recently, some are not 
legislated yet. Such substances are candidates for future regulation in case the toxicity, 
effects on public health and bioaccumulation studies indicate this requirement [3]. 
The expression “emerging micropollutants” is widely used to refer to these 
compounds, since they are usually found at low concentrations in the order of micro 
(μg/L) or nanogram per liter (ng/L) [4, 6]. These substances, even in small quantities, 
may cause adverse reactions to the organisms which they come into contact with [4]. 
2.2.1 Legislation 
Due to the low concentrations in which emerging micropollutants are found, their 
presence was only perceived with the development of new analytical methods and 
equipment [4]. In this way, most of the ruling legislations cover just the compounds that 
were already identified several years ago, such as organochlorine pesticides and aromatic 
hydrocarbons [12]. The methods of analysis and quantification of emerging 
micropollutants are still under development and study, as well as their effects on different 
organisms [6, 8–11]. Thus, the maximum amounts in which these substances could be 
found in nature have not been established yet in order to regulate these values [1, 12, 13]. 
Although legislation, usually, does not present limits for the concentration of 
emerging micropollutants in different environmental matrices, there are guidelines and 
monitoring activities for some candidate compounds for a future regulation [1, 12, 13]. 
In the European Union, for example, Directive 2008/105/EC presents list of 33 priority 
substances and their maximum allowable concentrations in aqueous matrices, which 
includes pollutants already characterized and traditionally legislated, such as benzene, 
naphthalene and hexachlorobenzene. In addition, this Directive indicates 11 substances 
for possible classification as priority in the future [5, 14–16]. 
Directive 2013/39/EU already presents 45 compounds in the list of priority 
substances and establishes a surveillance list with compounds that indicate risk to the 
aquatic environment and whose monitoring data are still insufficient. Among the 
substances on the watch list are diclofenac, 17-beta-estradiol and 17-alpha-eylestradiol, 
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being them, respectively, an anti-inflammatory, a natural hormone and a synthetic 
hormone utilized in contraceptives [15, 17]. 
2.2.2 Emerging micropollutant classes 
Emerging micropollutants belong to very different groups of substances, such as 
pharmaceuticals, cosmetics, surfactants, pesticides, cleaning products, illicit drugs, flame 
retardants, nanomaterials and others [5, 18]. Due to the lack of a specific legislation for 
emerging micropollutants, there is no standard classification for them. However, the most 
common classification found in the literature is separated in Persistent Organic Pollutants, 
Pharmaceuticals and Personal Care Products and Endocrine Disrupting Compounds [6, 
7, 19]. 
Persistent organic pollutants, also called POP, are organic compounds of difficult 
degradation, either by chemical, physical or photolytic agents. Due to this characteristic, 
these substances can accumulate in human or animal tissues and can also be inserted into 
the food chain. In this group, there are also some pesticides, such as hexachlorobenzene 
and DDT (dichlorodiphenyltrichloroethane), brominated flame retardants and 
organometallic compounds [11]. As a result of bioaccumulation and biomagnification 
properties, these compounds may be carcinogenic or mutagenic [1]. 
Pharmaceuticals and Personal Care Products (PPCP) form a very diverse class. It 
includes medicines, fragrances, disinfectants, sunscreen agents, preservers agents, X-ray 
contrasting substances, illicit drugs, veterinary drugs, cosmetic additives and others [6, 
20–22]. Many of these compounds are water soluble, so their presence is quite common 
in environmental hydric systems due to wastewater, leachate of sanitary landfills or septic 
tanks [11]. 
Endocrine Disrupting Compounds (EDC) are substances capable of inhibiting the 
function of natural hormones or assuming their function, altering their production. By 
modifying the endocrine functions of a living being, they can cause behavioral, 
reproductive or development changes of the organism. Some compounds belonging to 
this class are natural or synthetic hormones, such as 17-beta-estradiol, 17-alpha-estradiol, 
and some pesticides, such as carbofuran [11]. 
Table 1 presents some studies that aimed to measure some emerging 
micropollutants found in aqueous matrices. 
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Table 1. Some studies on emerging micropollutants found in the literature. 








Acetylsalicylic acid Sewer SPME/GC-MS 27000 2018 [24] 
Azithromycin Surface water 
SPE/UHPLC–
MS/MS 
30.00 2018 [25] 









8.93 2013 [14] 
Diclofenac 
Sewer water SPE/LC-MS 100 2011 [11] 
Sewer SPME/GC-MS 300 2018 [24] 
Ibuprofen Sewer SPME/GC-MS 10100 2018 [24] 
Naproxen Sewer SPME/GC-MS 11000 2018 [24] 
Miconazole Sewer water SPE/LC-MS 13.9 2011 [11] 
Sulfamethoxazole Sewer water SPE/LC-MS 13 2011 [11] 
Triclosan Surface water 
SPE/HPLC-
DAD 
28.43 2011 [26] 
Trimethoprim Sewer SPE/LC-MS 61 2011 [11] 
EDC 
Bisphenol A 








5 2013 [14] 
Estriol Surface water 
SPE/HPLC-
DAD 
5.39 2011 [26] 
Estrone Surface water 
SPE/HPLC-
DAD 
4.9 2011 [26] 
Testosterone Surface water 
SPE/HPLC-
DAD 













556.66 2018 [25] 
This information shows that compounds from all the mentioned classes were 
found in the recent years in different aqueous matrices and with a wide range of 
concentrations. 
2.2.2.1 Pharmaceuticals and personal care products  
Pharmaceutical and Personal Care Products (PPCP) are known as pseudo 
persistent pollutants because although they are not really resistant to degradation like 
 
10 
POP, they are continuously reintroduced into the environment. Due to their massive 
consume, substantial amounts reach hydric media again, maintaining significant amounts 
in water systems [20, 21, 24]. Drugs are defined as therapeutic substances used to prevent 
or treat diseases in humans or animals. The personal care products are used to improve 
the quality of human life [22].  
Pharmaceutical compounds are generally organic, moderately soluble in water 
and lipophilic. They are substances with medicinal properties that can be administered 
topically (local application on skin or mucosa), internally (usually orally) or parenterally 
(such as injections), under different forms [28]. These substances are produced with high 
pharmacologic activity, that means they perform their functions even at low 
concentrations [6]. The pharmaceutical industry is one of those with largest expansion in 
the global economy. It is estimated that in 2010, the sale of drugs produced profits of 
more than 780 billion euros. The European Federation of Pharmaceutical Industries and 
Associations (EFPIA) data show that the investments in research and development for 
pharmaceutical industries are rising year after year, with a perspective of 140 billion euros 
until 2020. In Europe, pharmaceutical industry employed more than in 747 thousand 
people in 2016 [29]. Worldwide, the antibiotics are the most prescribed medications and 
each year more than 12000 tons of these compounds are prescribed [30]. 
The presence of these chemical compounds in the environment does not 
automatically means an environmental problem. However, from the first evidence that 
such products may cause damage or other consequences to aquatic life or human beings, 
more attention should be given to this problem [22]. Despite their importance in society, 
preventing and healing diseases, drugs can cause harm to health when consumed through 
an incorrect method or in wrong quantities. It was believed that the main cause of 
inadequate ingestion of these compounds was self-medication, which could lead to 
consumption in higher quantities than the recommended ones. However, the development 
of more sensitive analytical techniques in recent decades has evidenced the contamination 
of water by drugs, that combined with their high pharmacological activity, can also cause 
reactions in the organisms with which they come into contact [9, 27]. 
The spreading of medications and water contamination can occur by different 
routes: launching of residues during the production of these compounds in industries, 
excretion of substances by the organism after ingestion, disposal of expired products and 
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use of animal manure as fertilizers [6]. Figure 1 presents a flowchart with the main routes 
of environment contamination by drugs [10, 25]. 
 
Figure 1. Sources and routes of contamination of water for consumption. 
Among the water contamination pathways exposed above, such as aquaculture, 
soil, sewage treatment plants, landfills, industrial wastewater treatment plants and direct 
discards of residues from the pharmaceutical industries, the last two are the most 
controlled ones, as there are rules legislating and regulating the quality of the effluents 
thrown by the plants [6]. However, it is difficult to measure the elimination of these 
compounds by the organisms. It is known that the quantities ingested from a medicine are 
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not fully metabolized, and a part of them are discarded, mainly by urine. This happens 
both in humans and in animals and in different quantities according to each organism. 
However, animal manure is usually deposited directly into the soil without going through 
any sort of prior treatment [9, 13, 25, 27]. 
Although not considered persistent pollutants and found in low concentrations, 
the drugs can reach aquatic life and cause unexpected reactions. The most noticeable 
effects caused by these substances are the natural selection of microorganisms that can be 
resistant to some antibiotics and the harmful influence on the reproductive system of 
aquatic beings [8].  
Different studies have found PPCP in fish, algae and mosquitoes [22]. Since these 
compounds were not developed to act in these living beings, the active principles and 
their derivatives can cause alterations or accumulate in their organism. In addition, certain 
drugs may promote adverse reactions when interacting with each other, and may impair 
human and animal health [32]. Another aggravating factor is the fact that these 
compounds are developed to present a high pharmacological potency, which means that 
they can cause the desired effects in a substantial way even at low concentrations and 
retain their physicochemical properties long enough to serve to the therapeutic purpose 
developed [4, 10, 11, 21]. 
The physicochemical characteristics of these compounds hinder their removal by 
conventional processes of water and wastewater treatment. There are several studies 
showing that although different treatment techniques are used, significant amounts of 
PPCPs still reach the water systems [2, 4, 21, 22, 29, 30]. Usually, the processes used to 
remove PPCP are physical, biological or chemical. The most common physical method 
is adsorption, which consists of transporting the pollutants from the effluent to the surface 
of the adsorbent material, which may be activated charcoal, graphene, carbon nanotubes, 
among others [21]. The methods of biological degradation are those that have lower cost 
and less complex operation, because they use microorganisms that incorporate pollutants 
as compounds for their metabolic functions [21]. In the literature, the most mentioned 
chemical process for degradation of these compounds is oxidation. Some of the 




The drugs can be subdivided in different classes according to the application they 
are intended for. Among them there are analgesics and anti-inflammatories, antibiotics, 
antiepileptic, contrasting, synthetic steroids and others can be cited [9, 20]. 
Analgesics and anti-inflammatories are drugs used to reduce pain and 
inflammation and do not require medical prescription. The most common are paracetamol 
(acetaminophen), aspirin (acetylsalicylic acid), diclofenac and ibuprofen [9, 20]. 
Antibiotics have the function of assisting the treatment of microbiological 
infections eliminating bacteria in the organism, both of animals and humans. In this 
group, it is possible to mention sulfamethoxazole, azithromycin, amoxicillin and 
penicillin [6, 9, 31].  
Lipid regulators are substances that help to control cholesterol and triglycerides 
in the blood. Some of these compounds found in studies in aqueous matrices were 
clofibrate and bezafibrate, the latter being one of the most used drugs in the world [6, 20, 
21]. 
Beta-blockers can inhibit the release of adrenaline and noradrenaline, promoting 
the control of cardiovascular diseases and arterial hypertension. The most consumed are 
atenolol, propranolol and metoprolol [12, 20, 22, 31]. 
Table 2 shows some studies in which the authors quantified the concentrations of 
some drugs in the environment. These studies evidences that a wide range of 




Table 2. Classes of pharmaceutical drugs quantified in selected literature studies. 






Sewer SPE/LC-MS 100 2011 [11] 
Groundwater SPE/LC-ESI-MS/MS 0.41 2013 [36] 
Ibuprofen 
Groundwater SPE/LC-ESI-MS/MS 87.05 2013 [36] 
Effluent LLE/GC-MS 15530 2014 [37] 
Antibiotic 
Azithromycin 
Surface water SPE/RP-LC-MS-MS 0.45 2014 [38] 
Groundwater SPE/LC-ESI-MS/MS 15.09 2013 [36] 
Sulfadiazine Surface water SPE/RP-LC-MS-MS 21.45 2014 [38] 
Sulfamethoxazole 
Sewer SPE/LC-MS 13 2011 [11] 
Surface water SPE/RP-LC-MS-MS 9.65 2014 [38] 
Surface water SPE/LC and SPE/GC 113 2014 [39] 
Sulfathiazole Surface water SPE/RP-LC-MS-MS 2.1 2014 [38] 
Trimethoprim 
Sewer SPE/LC-MS 61 2011 [11] 
Surface water SPE/RP-LC-MS-MS 13.1 2014 [38] 
Surface water SPE/LC and SPE/GC 0.7 2014 [39] 
Antiepileptic Carbamazepine Surface water SPE/LC and SPE/GC 72 2014 [39] 
Antifungal Miconazole Sewer SPE/LC-MS 13.9 2011 [11] 






Table 2. Classes of pharmaceutical drugs quantified in selected literature studies (continuation). 





Surface water SPE/HPLC-DAD 4.46 2011 [26] 
Effluent LLE/GC-MS 360 2014 [37] 
Treated water SPE/HPLC-MS/MS 8.93 2013 [14] 
Lipid regulators 
Gemfibrozil 
Surface water SPE/LC and SPE/GC 1.2 2014 [39] 
Groundwater SPE/LC-ESI-MS/MS 0.41 2013 [36] 
Bezafibrate 
Groundwater SPE/LC-ESI-MS/MS 3.36 2013 [36] 





2.3 Compounds of interest 
In an effort to select the compounds to be analyzed in this study, it was necessary 
to investigate which of the multiple types of drugs would be more frequently found in 
aqueous matrices of Bragança. 
After examining studies with a similar theme conducted in northern Portugal or in 
regions with socio-economic characteristics similar to Bragança, the following 
compounds were selected: ibuprofen, diclofenac, naproxen, ketoprofen, acetylsalicylic 
acid, azithromycin, sulfamethoxazole, carbamazepine, acetaminophen and caffeine [8, 
36–39]. 
2.3.1 Anti-inflammatory 
Ibuprofen, diclofenac, naproxen, ketoprofen and acetylsalicylic acid are non-
steroidal anti-inflammatory drugs (NSAID), one of the most widely used drug classes 
worldwide [44]. As all the anti-inflammatories, their function is to combat inflammations 
and to reduce pain and fever, however the difference from steroidal anti-inflammatory 
drugs (SAID) is the performance at different moments of inflammatory action, each one 
of these two classes being indicated for different forms of inflammation [45]. NSAID are 
usually recommended for musculoskeletal, urinary and intestinal inflammations, while 
allergic diseases are often treated with SAID [40, 41]. NSAID, however, are more used 
because the cases that require them are more frequent than those that require SAID [45]. 
2.3.1.1 Ibuprofen 
The propanoic 2-(4-isobutylphenyl) acid, whose chemical structure is presented 
in Figure 2, is the third most consumed drug in the world, with a production that reaches 
kilotons [43]. It is a compound that, under ambient conditions, presents itself in the form 
of a white powder of weak odor and that can be absorbed by ingestion or contact with 




Figure 2. Ibuprofen chemical structure. 
2.3.1.2 Diclofenac 
Diclofenac is a NSAID derived from phenylacetic acid, usually used as sodium or 
potassium salt, commonly consumed orally or topically. It is a drug indicated for 
intervention in mild to moderate pain and clinical and post-operative inflammations [48]. 
Its chemical structure is presented in Figure 3. 
 
Figure 3. Sodium diclofenac chemical structure. 
2.3.1.3 Naproxen 
Naproxen is the active ingredient of medicinal products such as Naprosyn®, 
Flamaprox® and Flanax®, used for the relief of acute pain with inflammatory component, 
musculoskeletal circumstances such as torticollis, or post-traumatic conditions [49]. A 
manner to consume the compound is in the form of sodic salt, whose chemical structure 
is shown in Figure 4. 
 
Figure 4. Sodium naproxen chemical structure. 
2.3.1.4 Ketoprofen 
Ketoprofen is the main compound present in Profenid®, Flamador®, Artrosil®, 
Menarini®. It is an anti-inflammatory drug mostly used to treat rheumatism consequences, 





Figure 5. Ketoprofen chemical structure. 
2.3.1.5 Acetylsalicylic acid 
The acetylsalicylic acid is an anti-inflammatory drug that also avoids the grouping 
of platelets, preventing clots as well. It is an odorless white crystal usually consumed in 
pills and the main compound of Aspirin® [49, 50] . The chemical structure of 
acetylsalicylic acid is showed in Figure 6. 
 
Figure 6. Acetylsalicylic acid chemical structure. 
2.3.2 Antibiotics 
Antibiotics are natural or synthetic substances used to treat or prevent bacterial 
infections, killing bacteria or avoiding their proliferation [46–48]. The year 1928 is 
considered the milestone for the treatment of bacterial diseases due to the discovery of 
penicillin by Alexander Fleming, although this was not the first identified antibiotic and 
was adopted as a therapeutic compound only in 1940 [55]. Currently there are several 
classes of these drugs, divided by the mechanism of antibiotic action, since each one acts 
in one of the many enzymes necessary for the metabolism of bacteria [55]. 
2.3.2.1 Azithromycin 
Azithromycin is an antibiotic of the macrolide group, which acts interfering in the 
synthesis of bacterial proteins. It is generally indicated to combat respiratory infections 
such as pneumonia, chronic bronchitis, among other diseases [55]. Its chemical structure 




Figure 7. Azithromycin chemical structure. 
2.3.2.2 Sulfamethoxazole 
Sulfamethoxazole, presented in Figure 8, is an antibiotic belonging to the 
sulfonamides group, which blocks the necessary enzymes for the synthesis of nucleic 
acids from bacteria. It is widely used to cure urinary infections and HIV-infected patients 
affected by some opportunistic infections such as pneumocystosis [55]. 
 
Figure 8. Sulfamethoxazole chemical structure. 
2.3.3 Other commonly used drugs 
2.3.3.1 Carbamazepine 
Synthesized for the first time in 1953, carbamazepine is an antiepileptic, but it is 
also used to control hyperactivity, bipolarity and schizophrenia. As epileptic crises occur 
when there is uncontrolled electrical activity in the brain, these episodes happen often, 
but unpredictable. Antiepileptic agents act in such a way to inhibit neuronal activity or 
reduce their excitatory activity [57]. The action of the carbamazepine as an antiepileptic 
happens in order to prevent the flow of sodium ions in the neuronal membranes, 
stabilizing them and restricting the synapses of excitatory impulses [57]. The Figure 9 




Figure 9. Carbamazepine chemical structure. 
2.3.3.2 Acetaminophen 
Acetaminophen or paracetamol (Figure 10) is an analgesic and antipyretic drug. 
It is the active principle of commercial products as Tylenol®, Cimegripe®, Panadol® and 
Vick Pyrena®. This compound is typically used to treat toothache, adverse reactions of 
vaccines, headache and flu symptoms, such as fever [55, 56]. 
 
Figure 10. Acetaminophen chemical structure. 
2.3.3.3 Caffeine 
The caffeine (Figure 11) is a compound present in over sixty species of plants. It 
was isolated in 1820, but its effects were recognized only in 1981. It is present in several 
foods and beverages consumed worldwide besides in medical drugs. Different analgesics 
contain caffeine combined with acetaminophen or NSAID [57, 58] . Due to these two 
possible sources of caffeine to the environment, this molecule may be an indicator, 
showing that the matrix can be contaminated with other compounds. That means that 
despite not being a proven harmful substance, the detection of caffeine shows a high 




Figure 11. Caffeine chemical structure. 
Table 3 summarizes some physicochemical characteristics of the compounds of 
interest discussed in this section. 











Acetaminophen C8H9NO2 103-90-2 151.17 14000 9.38 [63] 
Acetylsalicylic 
acid 




748.99 2.37 8.74 [64] 
Caffeine C8H10N4O2 58-08-2 194.194 11000 10.4 [65] 
Carbamazepine C15H12N2O 298-46-4 236.27 18 13.9 [66] 
Diclofenac sodium C14H10Cl2NO2Na 
15307-
79-6 








254.29 51 4.45 [68] 
Naproxen Sodium C14H13NaO3 
26159-
34-2 
252.00 15.9 4.2 [69] 
Sulfamethoxazole C10H11N3O3S 723-46-6 235.30 610 5.7 [16] 
 
2.4 Review of experimental methodologies for drugs analysis 
It was necessary to research similar studies in the literature in order to understand 
the approach generally used to analyze the selected compounds. Thus, it was possible to 
verify which methods of extraction, identification and quantification can be used in a 




Table 4. Main analytical methods found in literature for some pharmaceutical drugs. 











SPE (Bond Elut® 
500 mg/5 mL) 
HPLC-DAD 170 <LOQ [70] 
Affluent ETP SPE (Oasis MAX 6cc 150 mg) HPLC-DAD 0.1 62 [71] 
Effluent ETP SPE (Oasis MAX 6cc 150 mg) HPLC-DAD 0.1 3.15 [71] 
Hospital 
effluent 
LLE (Chloroform) HPLC-UV 20 77.1 [72] 
Diclofenac 
Affluent ETP 
SPE Bond Elut® 
500 mg/5 mL 
HPLC-DAD 170 0.77 [70] 
Effluent ETP 
SPE Bond Elut® 
500 mg/5 mL 
HPLC-DAD 170 0.93 [70] 
Surface water 
SPE (Sampliq - OPT Agilent 
Technologies® 60mg/3mL) 
HPLC-DAD 1.1 <LOQ [73] 
Affluent ETP SPE (Oasis® MAX 6cc 150 mg) HPLC-DAD 0.4 11.2 [71] 
Effluent ETP SPE (Oasis® MAX 6cc 150 mg) HPLC-DAD 0.4 1.7 [71] 
Hospital 
effluent 
LLE (Chloroform) HPLC-UV 12 93.3 [72] 
Sewer 
SPE (Strata SAX® 500mg/6 mL e 





Azithromycin Wastewater SPE (Oasis® HLB 200 mg/6 mL) LC-MS-MS 0.013 2.686 [74] 
Carbamazepine 
Blood SPE (Oasis® HLB 3cc) UPLC-MS/MS 162.79 - [57] 






Table 4. Main analytical methods found in literature for some pharmaceutical drugs (continuation). 









Affluent ETP SPE (Oasis® MAX 6cc 150 mg) HPLC-DAD 0.4 17.5 [71] 
Effluent ETP SPE (Oasis® MAX 6cc 150 mg) HPLC-DAD 0.4 0.85 [71] 
Hospital 
effluent 
LLE (Chloroform) HPLC-UV 8 119 [72] 
Sulfamethoxazole 
Sewer 
SPE (Loss SAX® 500mg/6 mL And 





Surface water SPE (C18 Waters Sep-Then ®) HPLC-UV 1.1 <LOD [76] 
Ketoprofen 
Surface water SPE (Oasis HLB 6cc 200 mg) HPLC-DAD 0.26 1.55 [77] 
Wastewater SPE (Oasis HLB 6cc 200 mg) HPLC-DAD 0.26 4.3 [77] 
Acetylsalicylic 
acid 
Wastewater SPE (Oasis MCX 60 mg) 
UPLC–
ESI/MS/MS 
0.0005 0.966 [78] 
Surface water SPE (Oasis HLB 6mL 500mg) HPLC-DAD 0.548 0.469 [79] 
Acetaminophen 
Surface water SPE (Oasis HLB 6mL 500mg) HPLC-DAD 0.020 0.047 [79] 
Surface water SPE (Oasis MCX 60 mg) 
UPLC–
ESI/MS/MS 
0.012 0.212 [78] 
Caffeine Wastewater SPE (Oasis HLB 6cc 200 mg) GC-MS - 0.016 [80] 
 
* LOQ: Limit of quantification 
** ETP: Effluent treatment plant 
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From the information collected in Table 4, it is concluded that the most used 
extraction method is solid phase extraction (SPE). The SPE technique allows the study of 
samples with small concentrations, as is the case of micropollutant analyses, besides not 
needing large volumes of toxic solvents, as in the liquid phase extraction [11]. The selection 
of the cartridges for SPE is related to the affinity between the analyte and the adsorbent 
present in the cartridge. Both studies in Table 4 and studies by other authors do not present 
a conclusion of the most appropriate cartridge [70]. 
Regarding the quantification techniques, the most widely used method among the 
studies mentioned above was high performance liquid chromatography (HPLC) coupled to 
a diode array detector (DAD). However, many studies also use gas chromatography (GC) 
and other coupled techniques to quantification, such as mass spectrometry (MS), tandem 
mass spectrometry  (MS/MS), spectrophotometric detector in the ultraviolet region (UV) and 
flame ionization detector (FID) [10, 13, 59]. 
2.4.1 Solid phase extraction 
The solid phase extraction (SPE) technique was created during the 80s and has the 
purpose to extract and pre-concentrate the analytes from complex media. Unlike Liquid-
Liquid Extraction, SPE does not use high amounts of solvents, because it uses solid sorbent. 
The sample passes through the sorbent that retains the desired compounds due to specific 
polar interactions [1, 11, 68, 79]. 
The SPE cartridge is a syringe shape tube that contains the solid sorbent packed 
between two filters called frits. Presently, there is a massive variety of sorbents in the market, 
being each one of them employed for a specific type of interaction between the analyte and 
the matrix. For this reason, several solids were developed, to attend to different specifics 
purposes [11, 68, 79]. 
There are basically four steps during the SPE procedure as illustrated in Figure 12 




Figure 12. The four steps used in the SPE basic procedure. 
The first stage is the solid conditioning by adding a solvent that is able to activate the 
sorbent and to clean impurities that can be inside the cartridge. The second step is to 
percolate the sample through the solid, in order to retain the compound(s) of interest. This 
retention happens due to the polar interactions and due to the adsorption process. In this 
moment, some amount of impurities can also be retained in the solid. For this reason, there 
is the third step, the washing, which consists of adding a weak solvent to remove the 
impurities without removing the compound(s) of interest from the sorbent. Finally, the last 
stage is to elute the analyte(s) from the solid adding small volumes of a stronger solvent [11, 
68, 79, 80]. 
 




2.4.2 High performance liquid chromatography 
Chromatography is a technique that allows the separation of substances to promote 
their identification, quantification or purification. The sample passes through a stationary 
phase carried by a mobile phase. The separation is based on the different polar interactions 
between the compounds and the mobile and stationary phases. The analytes that interact 
more with the stationary phase take longer to cross it, while the other compounds leave the 
system faster. This is the main separation principle of chromatography [4, 11, 68, 71]. 
The main difference between gas chromatography (GC) and liquid chromatography 
(LC) is that for the first one, the mobile phase is a gas and for the second one it is a liquid. 
The stationary phase in GC is normally a capillary column and in LC is normally a packed 
column. Concerning chromatographic analysis of PPCP, the most used technique is high 
performance liquid chromatography (HPLC), because these compounds tend to be less 
volatile and to suffer degradation with high temperatures [11, 68]. After the chromatographic 
separation, the substances need to be identified by a detector [4, 11, 71]. Figure 14 shows a 
basic HPLC equipment layout. 
 
Figure 14. Basic HPLC equipment layout. 
As each analyte has different affinities with the phases, they left the column in 
different moments and are detected separately. Usually, the most used parameter to identify 
the compounds is their retention time, that represents the time required for an analyte to be 
detected after the sample has been injected [81]. 
For pharmaceuticals chromatographic separations, the most indicated solvent mode 
of HPLC is the reversed phase (RP-HPLC). This mode of chromatography employs a column 
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that is less polar than the mobile phase, which is normally a mixture of acetonitrile with 
water. The main stationary phases are, generally, silica supports modified with C8 or C18 
carbon chains [81, 82]. 
This type of chromatography is indicated to polar compounds due to the speed of 
analysis comparing to normal phase chromatography. It happens because, for a same set of 
experimental conditions, the retention of a compound in RP-HPLC depends on its polarity. 
Less polar molecules tend to interact more with the stationary phase, increasing its retention 
time, while more polar substances interact more with the mobile phase than with the 
stationary one, presenting a lower retention time [81, 82] 
2.4.2.1 Diode Array Detector (DAD) 
Different HPLC detectors respond to different physicochemical properties, such as 
UV absorbance, mass charge ratio, fluorescence, refractive index, among others. Each 
detector measures one of these properties of the mobile phase as it flows and the detector 
response changes as the mobile phase contents changes [85]. 
Most HPLC methods use UV-visible detectors, due to their low cost, acceptable 
limits of detection and quantification, ease of use and because most of compounds has 
reasonably UV-visible absorbance. There are three main types of UV-Vis detectors: single 
wavelength, multiple wavelength or photodiode array (DAD) [81, 83, 84]. 
The single wavelength detectors can only use one wavelength to the analysis, being 
the most common the value 254 nm, obtained from a low pressure mercury lamp. This is the 
reason why many studies with UV detector use this wavelength [86]. The multiple 
wavelength detector can be programmed to operate with a specific wavelength. This 
selection is made with a diffraction grating that rotates, directing a single wavelength, 
through a slit, to the flow cell [81, 84]. The photodiode array detector has a diffraction 
grating also, but it is located after the flow cell, so that several wavelengths pass through the 
sample and then reach the array of photodiodes. This way, it is possible to collect 
chromatograms at an entire light spectrum with a single run and a chromatogram at any of 
these wavelengths can be then displayed. Another information that can be displayed after 
the analysis is the UV spectrum of each analyte, that allows the selection of an optimum 
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wavelength for each analyte in the final HPLC method [79, 81, 84]. Figure 15 illustrates the 
operation of a photodiode array detector. 
 
Figure 15. Photodiode array detector scheme. 
The light from the emission source is collimated by a set of lenses and passes through 
the sample. After, the beam impinges the diffraction grating, separating the wavelengths and 
allowing that each one of them reaches a diode. The diodes convert the light intensity to a 
measurable output voltage sign, then an internal calibration system transforms this sign into 
an absorbance value for each wavelength, resulting in the absorbance spectrum of the sample 
[79, 81, 84]. 
 








2.5 Analytical methodology validation 
The analytical method development includes the validation process to measure its 
efficiency. The validation consists in guarantee, through objective criteria, that the method 
attends to its purpose, leading to reliable results [11, 68, 80, 85]. 
The validation parameters applied in this study are presented in the next sub-sections. 
2.5.1 Calibration curve and linearity 
During the method development it is necessary to build a calibration curve for each 
analyte, that is the graph between the standard solutions concentration, at X-axis, and their 
detected signal (in this case an area under the chromatographic peak), at the Y-axis [68, 71, 
80, 85]. 
The method of least squares was used in order to do the line of regression of the 
obtained data. Since the results should fit into a straight line, the calibration plots take the 
algebraic form of equation (1), where 𝑎 is the graph interception on y-axis, 𝑏 is its slope, 𝑦 
is the area of the peak and 𝑥 is the analyte concentration [88]. 
 𝑦 = 𝑎 + 𝑏𝑥 (1) 
The method of least squares is based on two main equations. Equation (2) gives the 
slope of least squares line, the b  coefficient. The intercept of least squares lines, 𝑎 
coefficient, is calculated through equation (3), where ?̅?  and ?̅?  are the mean values of 
concentration (𝑥𝑖) and area (𝑦𝑖) results, respectively [88]. 
 𝑏 =
∑ [(𝑥𝑖 − ?̅?) × (𝑦𝑖 − ?̅?)]𝑖
∑ (𝑥𝑖 − ?̅?)2𝑖
 (2) 
 
 𝑎 = ?̅? − 𝑏?̅? (3) 
Another important parameter is the product–moment correlation coefficient, 𝑟 , 
calculated through equation (4). This method is used to estimate how well the behavior of 
the experimental data fits to a straight line. The closer the correlation coefficient is to the 




∑ [(𝑥𝑖 − ?̅?) × (𝑦𝑖 − ?̅?)]𝑖
{[∑ (𝑥𝑖 − ?̅?)2𝑖 ] × [∑ (𝑦𝑖 − ?̅?)2]}𝑖
1/2
 (4) 
It is also possible to calculate the error 𝑆𝑦 𝑥⁄  associated to the slope and to the 
intercept of the regression line. Equation (5) shows its calculation, where 𝑛 is the amount of 
adjusted points and 𝑦?̂? are the values estimated with the regression line equation [88]. 
 𝑆𝑦 𝑥⁄ = √
∑ (𝑦𝑖 − ?̂?𝑖)2𝑖
𝑛 − 2
 (5) 
The standard deviations of slope and intercept can be calculated using equations (6) 
and (7), respectively [88]. 
 𝑆𝑏 =
𝑆𝑦 𝑥⁄
√∑ (𝑥𝑖 − ?̅?)2𝑖
 (6) 
 




𝑛 × ∑ (𝑥𝑖 − ?̅?)2𝑖
 (7) 
The 𝑆𝑦 𝑥⁄  parameter can be used to identify and reject outliers, abnormal results that 
inevitably occur in calibration procedures. A criterion usually applied is when the y-residual 
(𝑦𝑖 − ?̂?𝑖) is more than twice the value of the 𝑆𝑦 𝑥⁄  value. When this happens, the point must 
be removed from the fitting procedure [88]. 
The t-Student statistic distribution is used to provide the confidence limits (CL) for 
the slope and intercept as shown in equations (8) and (9) [88]. 
 𝐶𝐿(𝑏) = 𝑏 ± 𝑡 × 𝑆𝑏 (8) 
 𝐶𝐿(𝑎) = 𝑎 ± 𝑡 × 𝑆𝑎 (9) 
This statistic methodology can be used to find a concentration corresponding to an 
experimental measured signal, and the error associated to this concentration can be 
















2.5.2 Limit of detection 
The limit of detection (LOD) is the smaller amount of an analyte which can be 
detected, not necessarily quantified, within the experimental conditions stablished for the 
developed method. It can be valued trough three different ways by visual observation, with 
the signal/noise relationship and by means of the analytical curve parameters methods [11, 
68, 79]. 
The most usual way is the third one, that uses analytical curve parameters applying 
them to equation (11) [70]. 




2.5.3 Limit of quantification 
The limit of quantification (LOQ), is the smaller amount of an analyte which can be 
measured within the experimental conditions stablished for the developed method [68, 79]. 
It can be calculated by the following equation (12) [70]. 





Precision is the parameter that evaluates the results from different analysis for the 
same sample in the same conditions. It can be determined in two different cases: repeatability 
and intermediate precision [68, 74, 79, 80]. 
The first one expresses the precision among data obtained in a short interval of time, 
with the same materials, by the same operator in the same day. Usually, it can be evaluated 
with three different standard concentrations in triplicate or with six repetitions for a single 
standard concentration [70], [76], [81], [82]. 
The intermediate precision refers to the closeness among data achieved in different 
days, by different operators, with different materials. This approach is known as the most 
representative for the variability of results [70], [76], [81], [82]. 
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In both cases, the precision can be expressed as coefficient of variation (CV) or 
relative standard deviation (RSD), calculated using equation (13), where SD is the standard 
deviation and ?̅? is the average result [73]. 
 𝐶𝑉(%) = 𝑅𝑆𝐷(%) =
𝑆𝐷
?̅?
× 100 (13) 
2.5.5 Accuracy 
The method accuracy is the closeness between the experimental data and the true 
values. The exact value only can be defined by an absolutely perfect measurement, in doing 
so, this value cannot be defined [11, 68, 74, 79, 80, 85]. 
Accuracy is expressed as percentage systemic error and it is intrinsic to the method. 
A systemic error occurs due to the loss of the substance due to the small extraction recovery, 
inexact volumetric measurements or interfering substances in the sample [76]. 
The most usual process to evaluate the accuracy is through recovery measurements 
with the real matrix. Recovery represents the amount of a certain compound recovered in the 
process in relation to the real amount present in the sample, that is the reason why it can be 
employed to estimate accuracy [11, 68, 79]. 
For recovery measurements, the samples are fortified (spiked) with known quantities 
of analyte and the results obtained after extraction are compared with the initial ones before 
extraction for the same samples. Usually a real “clean” sample is used to avoid other 
interferers beyond those that already exists in the analyzed matrix [68, 79, 80]. 
The recovery percentage is calculated through the equation (14), where C1 is the 
measured concentration in the eluted sample, C2 is the measured concentration in not-




× 100 (14) 
2.5.6 Selectivity 
Selectivity represents the ability of the method to measure precisely the compound 
of interest without suffering interference from other substances or other analytes. If the 
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developed method is able to respond to different analytes distinguishing the responses 
among them, it is a selective method.[68, 74, 78]. 
This parameter is not measured, but it can be evaluated in different ways for 
chromatographic methods, such as comparing the analysis results of the matrix with and 
without the analytes and verifying if any other compound presents the same retention time 
that the compounds of interest. Another method is to employ detectors like photodiode array 
detector, which allows the analysis for several wavelengths and is also able to compare the 






























• Acetonitrile HPLC grade, Carlo Erba, +99.9% 
• Ultrapure water (resistivity value below 18.2 M.cm - Type I) 
• Commercial ethanol, Aga, 96% 
• Methanol HPLC grade, Carlo Erba, +99.9% 
• Trifluoracetic acid, Sigma Aldrich, +99% 
3.1.2 Standards and reagents 
• Ketoprofen, Sigma Aldrich, +98% 
• Naproxen, Alfa Aesar, +95% 
• Ibuprofen, Alfa Aesar, +99% 
• Diclofenac, Alfa Aesar, +95% 
• Acetylsalicylic acid, Alfa Aesar, +99% 
• Sulfamethoxazole, Sigma-Aldrich, +98% 
• Azithromycin, Sigma-Aldrich, +98% 
• Carbamazepine, Sigma-Aldrich, +97% 
• Acetaminophen, Alfa Aesar, +98% 
• Caffeine, Alfa Aesar, +99% 
3.1.3 Equipment 
• RHPLC Jasco system, Extreme model, equipped with a PU-4180 Pump, PDA 
MD-4010 detector, an Interface box LC-Net II/ADC and a manual Rheodyne 
injection valve 
• Chromatographic column EC Nucleosil 100-5, C18, 150mm L x 4.6mm ID, 
with a particle size diameter of 5 m, Macherey-Nagel 
• Analytical balance ADA 210/C, ±0.0002 g, Adam Equipment 
• pH meter HI 2020-02, Hanna 
• SPE cartridges, Chromabond HLB, 60 m;6 mL/500 mg, Macherey-Nagel 
• Visiprep™ SPE Vacuum Manifold, Supelco 
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• Millipore Direct Q3 UV Water Purification System, Merck 
3.2 Experimental methodology 
The study is divided in two main experimental steps. The first experimental task is 
to develop and optimize an experimental methodology to detect and quantify pharmaceutical 
drugs that belong to the class of non-steroidal anti-inflammatory drugs in different hydric 
media of the Bragança region. The proposed methodology is based on the solid phase 
extraction of analytes followed by detection and quantification using high performance 
liquid chromatography with a photo diode array detector. In this step, the main statistic 
parameters needed for method validation should be determined, such as the calibration 
curves, limits of detection and quantification, repeatability, accuracy and recoveries. The 
second experimental task will be the implementation of the developed methodology using 
some real aqueous samples collected from different points of the Bragança region. 
3.2.1 Analytical method development 
During the experimental work, all glassware was cleaned with detergent and 
abundantly rinsed with tap water, then rinsed with distillated water and finally with ethanol 
to remove any impurities. 
The stock solutions were prepared by measuring 100 mg of each standard into a 100 
mL volumetric flask and completing the remaining volume with the solvent used in each 
study, reaching a final concentration of 1000 mg/L. All prepared standard solutions were 
transferred to chromatography vials, sealed with film and stored at -18ºC until analysis. 
3.2.1.1 Effect of mobile phase composition on chromatographic separation 
The first variable to be optimized was the HPLC mobile phase composition. Several 
literature studies considering liquid chromatography of pharmaceutical drugs [11, 68, 77, 
85] mentioned the use of a solvent mixture between acetonitrile (ACN) and water (W) in 
different compositions, under either isocratic or gradient modes of operation. 
Initially, three mobile phases with different solvent proportions were tested in 
isocratic mode: 60ACN:40W, 50ACN:50W and 40ACN:60W. Due to the different polarities 
of acetonitrile and water, the interactions between the analytes and the mobile phase changes 
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for different compositions. Thus, the retention times and the dispersion of the 
chromatographic peaks are, generally, different for each solvent composition. 
For preliminary studies, and due to the available standards quantity, ketoprofen was 
selected as the prototype NSAID for preliminary measurements. Three ketoprofen standard 
solutions with a concentration of 100 ppm were prepared using the three different solvent 
compositions. These solutions were analyzed using the HPLC system with a flow-rate of 1 
mL/min and a 20 μL sample loop and the detector was set with a 254 nm wavelength, since 
some studies showed this value an appropriate wavelength for ketoprofen analysis [79]. 
3.2.1.2 Effect of mobile phase pH on chromatographic separation 
Since reverse-phase HPLC was the selected analytical method, it was important to 
control the pH value in the mobile phase, because the compounds of interest present a wide 
range of pKa values. At lower pH values, the concentration of H+ is higher, what inhibits the 
ionization of acid compounds (smaller pKa). When the compound is less ionized, it is less 
polar and has more interactions with the stationary phase (C18 column), enhancing the 
separation of acid compounds [79, 80, 87]. 
In order to study the pH effects on the retention times and dispersion, three 
60acetonitrile:40water mobile phases were evaluated, each one with a differed content of 
trifluoracetic acid (TFA): 0%, 0.01% and 0.1%. Three ketoprofen standards samples at 100 
ppm were prepared in 60ACN:40W solvent with the respective amounts of TFA for each 
analysis. The system was set up with a flow-rate of 1 mL/min and a wavelength of 254 nm, 
for the three analysis. 
Besides that, since the employed chromatographic column works in a pH range from 
2 to 8, it was necessary to define a safe proportion of TFA in the mobile phase. For these 
experiments, the pH values were measured in 60ACN:40W mixtures prepared with different 
contents of TFA that ranged from 0% to 0.1%. 
3.2.1.3 Study of the elution order and selection of the individual wavelengths 
Individual stock solutions at 1000 ppm for the ten standards were prepared with 
60ACN:40W:0.01TFA. The working solutions at 100 ppm were prepared by diluting the 
stock solutions with the same solvent. The equipment operated with the 
60ACN:40W:0.01TFA mobile phase, with a flow-rate of 1 mL/min and a wavelength range 
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from 190 to 650 nm. The aim of these measurements was to find out the elution order of the 
compounds and the wavelength that could allow a maximum absorbance value. 
The HPLC-DAD equipment can work up to four chromatograms in real time during 
each analysis, each one for one predefined wavelength. However, after each run, the software 
allows to create several virtual digital channels with different functions. One of the virtual 
channels that can be generated is a total chromatogram for a given wavelength that gives a 
maximum absorbance value. Doing this for each individual standard analysis, it was possible 
to find out the exact wavelength corresponding to the maximum absorbance for each 
compound. 
3.2.1.4 Standard mixture analysis 
From the stock solutions, a 60ACN:40W:0.01TFA mixture with each one of the ten 
compounds at 1 ppm was prepared and analyzed under different mobile phase compositions 
to verify if the compounds could be completely baseline resolved. Initially, the studied 
%acetonitrile:%water based compositions were 20:80, 30:70, 40:60, 50:50, 60:40, 70:30 and 
80:20, all solutions containing 0.01% of trifluoracetic acid. For all these analyses, the flow-
rate was kept at 1 mL/min. The monitored wavelengths were 202, 228, 254 and 280 nm. 
After, a 60ACN:40W:0.01TFA standard mixture, with NSAID only, was prepared 
with a concentration of 100 ppm for each anti-inflammatory to perform several gradients in 
order to study if a solvent gradient mode of operation could improve the baseline resolution 
for acetylsalicylic acid, diclofenac, ibuprofen, ketoprofen and naproxen. The wavelengths 





Table 5. Solvent gradient compositions studied for NSAIDs analysis. 
Gradient Time (min) ACN (%) W (%) Flow rate (mL/min) 
1 
0 15 85 
1.0 
4 15 85 
30 40 60 
80 70 30 
2 
0 50 50 
1.0 4 50 50 
20 80 20 
3 
0 60 40 
1.0 4 60 40 
20 80 20 
4 
0 23 77 
0.8 
60 23 77 
5 
0 60 40 
0.8 
60 60 40 
6 
0 60 40 
1.2 
60 60 40 
 
3.2.1.5 Linearity parameters of the HPLC analysis 
The calibration curves were built for each analyte, by preparing a stock mixture 
solution with all the five NSAID (acetylsalicylic acid, diclofenac, ibuprofen, ketoprofen and 
naproxen) with individual concentration of 1000 ppm in methanol. Using the stock solution, 
18 standard solutions were prepared for all the five standards with successive dilutions in 
methanol for the final concentrations from 100 ppm to 1 ppb. 
The analyses were carried out with 60ACN:40W:0.01% TFA using a flow-rate of 1.2 
mL/min. The monitored wavelengths were 219 nm for ibuprofen, 224 nm for acetylsalicylic 
acid and naproxen, 254 nm for ketoprofen and 275 nm for diclofenac. Each standard solution 
was injected three times. 
In order to evaluate the repeatability and intermediate precision, as explained in 
section 2.5.4, three concentrations were analyzed in triplicate for each analyte, considering 
their linear range. In Table 6 are presented the concentration values used for the precision 
studies for each substance. 
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For the repeatability evaluation, the standards with the selected concentrations were 
analyzed in three times in a row, at the same day, with the same solvents. For the intermediate 
precision, the standards were analyzed in different days, with prepared mobile phases 
prepared at the day of the analyses. The parameters were obtained using the equation (13) to 
calculate de coefficient of variation for each concentration. 










40 250 500 
Diclofenac 250 500 750 
Ibuprofen 50 250 500 
Ketoprofen 30 40 50 
Naproxen 30 40 50 
 
3.2.1.6 Solid phase extraction operating conditions 
The cartridge was chosen based on published references for pharmaceuticals 
extraction, as those referred in Table 4, comparing their results and searching for the 
composition of commercially available solids. It was concluded that an adsorbent based on 
poly (N-vinyl pyrrolidone-divinylbenzene), such as the Chromabond HLB 60 m/6 mL/500 
mg was the most suitable for this application. 
The adopted SPE methodology was based on the experimental procedure proposed 
by the manufacturer [90]. The solvents and the volumes for each stage are presented in Table 
7. The flow-rates were not referred by the manufacturer, therefore, in order to optimize them, 
for each step in each extraction, the dripping was adjusted to be as constant as possible and 




Table 7. Volumes for SPE steps [90]. 
Step Solvent Volume (mL) 
Conditioning A Methanol 5 
Conditioning B Water 5 
Loading Aqueous sample 10 
Washing Water 5 
Elution Methanol 8 
The first extractions were carried out employing individual standard solutions 
prepared in ultrapure water. The concentration for each compound was different due to their 
solubility in water. The values are listed in Table 8. 
Table 8. Standard solution concentration in the individual SPE extractions. 
Compound Concentration (ppm) 





After all the individual extractions measurements, a mixture was prepared measuring 
20 mL of each individual standard solution for a total mixture volume of 100 mL. The 
concentrations in the final standard mixture solution for each compound are presented in 
Table 9. 
Table 9. Standard mixture solution concentrations for the SPE extraction. 
Compound Concentration (ppm) 





One of the most important parameters to evaluate the SPE experimental methodology 
is the recovery. The measurements are usually carried out with spiked samples, prepared by 
adding known amounts of the analyte into real samples that do not contain any trace of the 
studied compound. In this study, the recovery was calculated through the analysis of samples 
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prepared in ultrapure water, therefore, the term C2 of equation (14) is equal to zero. So, in 
the modified equation (15) C1 is the concentration of analyte in the eluted solution and C3 is 
the concentration of analyte in the standard solution. Considering that the loading is done 
with 10 mL of the sample and the elution uses 8 mL of methanol, the elute is more 
concentrated than the original sample, for this reason, the concentration basis recovery may 
present values above 100%. 
 𝑅 (𝑐/𝑐) =
𝐶1
𝐶3
× 100 (15) 
Another way to evaluate the extraction is the mass basis recovery given by the 
equation (16), where m2 represents the analyte mass added to the cartridge and m1 is the 
recovered mass measured after the elution. 
 𝑅 (𝑚/𝑚) =
𝑚1
𝑚2
× 100 (16) 
Another way to evaluate the extraction is to calculate the recovery in a mass basis, 
using equation (15). However, the mass basis recovery, equation (16) is a useful parameter 
for the daily evaluation, since it ranges from 0 to 100%, being easier to understand its 
meaning. 
After each extraction procedure, the loading and washing wastes were analyzed to 
check if there was some loss of analyte in the wastes, as well as the eluate and the sample 
were also analyzed to calculate the extraction recovery. In this recovery studies, all the 
following HPLC analysis were performed with a 60acetonitrile:40water:0.01TFA solvent 
composition with a flow-rate of 1.2 mL/min and the DAD detector was set at 219, 224, 254 
and 275 nm wavelengths. 
3.2.2 Implementation of the developed methodology 
The experimental implementation of the developed methodology was done by 
collecting six samples in different locations and hydric sources in the Bragança region. The 
samples were collected in sterile amber flasks, stored in ice and transported to the laboratory. 
Then where 15 mL of each sample were measured and filtered with a 0.45 µm 
polytetrafluoroethylene filter and store in freeze (-18ºC) until the moment of analyses. These 
samples were named from S1 to S6, as described below. 
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• S1 – Tap water from municipal water distribution system; 
• S2 – Tap water from groundwater that supplies the Polytechnic Institute of Bragança; 
• S3 – Surface water from River A, location 1, collected at Polis; 
• S4 – Surface water from River A, location 2, collected inside IPB campus; 
• S5 – Surface water from River B; 
• S6 – Pool water from municipal sports facilities. 
The SPE extraction procedure was carried for each sample, at room temperature 
according to the developed methodology. In Table 10 is presented the SPE procedure applied 
for all samples (S1 to S6). 
Table 10. Final optimized flow-rates used in the SPE procedure for all samples. 
Step Solvent Volume (mL) Flow-rate (mL/min) 
Conditioning 1 Methanol 5 0.22 
Conditioning 2 Water 5 0.51 
Loading Sample 10 0.53 
Washing Water 5 0.87 
Elution Methanol 8 0.18 
The eluted samples were stored in the freezer until the moment of their analysis. Each 
eluted solution was injected three times. In Table 11 is shown the chromatographic operating 
conditions for the optimized HPLC method. 
Table 11. Operating conditions and parameters for HPLC analysis. 
HPLC-DAD 
Mobile phase composition 60acetonitrile:40water:0.01TFA 
Flow-rate 1.2 mL/min 
pH 2.5 
Column Nucleosil C18 (150mm x 3 mm) 
Sample injection volume 20 µL 
Monitored wavelengths 219, 224, 254 and 275 nm 

























4. Results and discussion 
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4.1 Analytical methodology development 
This section comprises the main results that lead to the final analytical methodology 
developed in this work. 
4.1.1 Effect of mobile phase composition in chromatographic separation 
The obtained chromatograms for the different studied mobile phases are overlaid in 
Figure 17. These results show that the increase of acetonitrile content in the mobile phase 
decrease significantly the retention time of ketoprofen and also improves the shape of the 
chromatographic peak (it is thinner and taller), decreasing the dispersion. This fact could be 
important in order to obtain higher resolution and improve the analytes identification. 
 
Figure 17. Study of ketoprofen (100 ppm) separation using different acetonitrile:water mobile 
phase volumetric compositions without pH modifier (0%TFA). 
This behavior was already expected, since different compositions result in different 
interactions between the analytes, the solvent and the stationary phase. In this case, due to 
the relative polarity of ketoprofen, the rise of acetonitrile content will increase the solvent 
apolarity, impairing the interaction with the stationary phase and promoting the interaction 
with the solvent. 
4.1.2 Effect of mobile phase pH on chromatographic separation 
In Figure 18 it is shown the experimental chromatograms obtained with 0, 0.01 and 
0.1% of TFA in the mobile phase. All the three mobile phase solutions were prepared with 
60ACN:40W with each one of the above referred proportions of acid. It must be emphasized 





Figure 18. Study of ketoprofen (100 ppm) separation using 60% acetonitrile and 40% water as 
mobile phase composition with different acidic modifier contents. 
As expected, the more acid is the mobile phase, less ionized and less polar are the 
analyte molecules, increasing the retention times. The peak shape was also improved with 
the increase of TFA. These results show that 0.01 and 0.1%TFA led to very similar retention 
times, however, the 0.1%TFA content presents higher intensity value, what can result in 
better detection limits. Knowing that the pH value of the mobile phase influences the 
separation and that the used chromatographic column (C18) has a safety working pH range 
from 2 to 8, the pH values for several 60ACN:40W mixtures were evaluated as a function 
of the amount of TFA. These results are presented in Table 12. 
Table 12. Effect of TFA content on the pH value using 60ACN:40W mobile phase composition. 
% TFA 0 0.001 0.005 0.01 0.02 0.03 0.04 0.05 0.10 
pH 8.19 3.46 2.57 2.50 2.32 2.19 2.09 2.02 1.66 
As referred above, the 0.1%TFA content presents better results if compared with the 
0.01%TFA. Nevertheless, the column lifetime will be affected considering that 0.1%TFA 
represents a pH value of 1.66 that is below the minimum value recommended by the 
manufacturer. 
4.1.3 Study of the elution order and selection of the individual wavelengths 
After each individual NSAID analysis, one virtual channel was used to generate the 
chromatogram at the wavelength with the highest absorbance. One wavelength was obtained 
for each one of the individual compounds and was selected for monitoring the detector signal 
for that compound. In Appendix A are presented the absorption spectrum for each analyte. 
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The retention time of the compounds using the 60ACN:40W:0.01%TFA mobile 
phase with a flow-rate of 1 mL/min and the optimum selected wavelengths, are described in 
Table 13. 
Table 13. Maximum absorbance wavelength and retention time for each compound of interest. 
Micropollutant UV-DAD Wavelength (nm) Retention time (min) 
Azithromycin 198 1.243 
Acetaminophen 245 1.783 
Caffeine 272 1.967 
Acetylsalicylic acid 224 2.210 
Sulfamethoxazole 268 2.210 
Carbamazepine 284 2.820 
Ketoprofen 254 3.310 
Naproxen 224 3.403 
Diclofenac 275 4.913 
Ibuprofen 219 5.237 
Usually, the criteria employed to recognize one compound in a chromatogram is its 
retention time. However, this parameter depends on the HPLC operating conditions and 
other compounds can present the same retention time, resulting in wrong identification and 
quantification. Using a DAD detector, it is possible to analyze the sample in the whole 
spectrum, allowing the introduction of the wavelength as a new parameter for the 
identification and/or quantification of the compounds [81]. This way, it is possible to study 
a compound at the wavelength where it responds the most. For this reason, knowing the 
maximum absorbance wavelength is very important to identify the substances in a mixture. 
4.1.4 Standard mixture analysis 
In this step, a mixture containing all the ten compounds was used with individual 
concentrations of 1 ppm. This mixture was analyzed, and the obtained chromatograms are 







Figure 19. HPLC-DAD chromatograms for different acetonitrile:water volume proportions. 
19a: 20ACN80W; 19b: 30ACN70W; 19c: 40ACN60W; 19d: 50ACN50W; 19e: 60ACN40W; 








The results showed that increasing the water content in the composition, increases 
the retention time and the dispersion of the peaks. That means that, in order to separate all 
the peaks, it would be necessary to use a mobile phase with a higher percentage of water, 
nevertheless this would result in lower peaks, prejudicing the limit of detection of the 
method. Based on these results and on the considerations about the pH and pKa explained 
on topics 3.2.1.2 and 4.1.2, it was decided that it would be better to develop two different 
methods. The first one, that will be presented in this work, will be developed for compounds 
with low pKa values, between 3.5 to 4.9, (acidic compounds, such as the anti-inflammatory 
drugs) and the second one for compounds presenting higher pKa values (basic compounds). 
For this reason, some mobile phase gradients were set up and tested in order to try to 
optimize the baseline separation, improving the quality of the method for the acid 







Figure 20. HPLC-DAD chromatograms for NSAIDs analysis with the 6 gradients previously 
referred in Table 5, page 39. 
20a: Composition 1; 20b: Composition 2; 20c: Composition 3; 20d: Composition 4; 20e: 
Composition 5 and 20f: Composition 6. 
Composition 6 was chosen to be used in the final method despite of not presenting a 
baseline resolution for all the 5 selected compounds. However, each compound responds in 
a different wavelength from the others, making possible an individual identification and 
quantification. The individual retention times obtained for each NSAID with 60ACN:40W: 







Table 14. Retention times for each analyte with composition 6. 
NSAID Retention time (min) 






4.1.5 Linearity parameters of the HPLC analysis 
In order to calculate the linearity parameters and the linear equation for each one of 
the five NSAID, only the lowest 6 to 8 concentrations levels were considered, since these 
compounds are considered to be found in very low quantities. The linearity results are 
presented in Table 15 and all the experimental and calculated data for this linearity study is 
presented in Appendix B. 











40 - 5000 8 
21.71 ± 
0.29 
359.80 ± 536 0.9989 74.00 246.67 





0.9996 60.01 200.04 
Ibuprofen 30 - 500 6 
79.09 ± 
0.48 
283.85 ±112 0.9999 4.24 14.12 





0.9976 2.24 7.46 





0.9876 5.09 16.98 
Comparing these results with other already published studies, referred in Table 4, the 
achieved limits of detection and quantification were a little higher than those from the 
compared studies. Considering only similar methodologies (SPE/HPLC-DAD) it can be 
observed that for acetylsalicylic acid, the obtained LOQ value (246.67 ppb) is higher than 
the presented in reference [79] (0.548 ppb). The obtained LOQ value for diclofenac (200.04 
ppb) is similar to the referred in reference 67 (170 ppb), but considerably higher than that 
the referred in reference [71] (0.4 ppb). For ibuprofen the obtained LOQ value (14.12 ppb) 
is between the value referred in reference [70] (170 ppb) and the value referred in reference 
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[71] (0.1 ppb). For ketoprofen the obtained LOQ value (7.46 ppb) is higher than the value 
referred in reference [77] (0.26 ppb). For naproxen the obtained LOQ value (16.98 ppb) is 
higher than the values referred in reference [71] (0.4 ppb). 
Different reasons can explain these differences in the LOQ and LOD values obtained 
in this work from others already published. The most important hypothesis can be related to 
the fact that after a carefully reading of other works, it is possible to find different methods 
for the LOD and LOQ calculation. Another one could be related to the pH value of the mobile 
phase. Results presented in Figure 18 show that the pH values and the size of peak are related. 
The chromatogram for the analysis with lower pH showed higher peaks, what could 
consequently improve the limits of detection and quantification. Nevertheless, the employed 
chromatographic column was not designed to work in pH values under 2, so the 0.01% TFA 
proportion was the best one for the available column. 
Concerning to the precision parameters, Table 16 shows the results for coefficients 
of variation (CV) for the analyses of the concentrations selected (Table 6) to evaluate the 
repeatability and the intermediate precision. 
Table 16. Coefficients of variation for the selected concentrations for each compound for 
repeatability and intermediate precision. 
Compound 
Repeatability (%) Intermediate precision (%) 
C1 C2 C3 C1 C2 C3 
Acetylsalicylic acid 1.96 2.29 2.32 4.77 9.27 2.37 
Diclofenac 2.02 0.94 1.84 1.91 1.54 0.43 
Ibuprofen 1.28 1.64 0.25 0.97 2.34 4.91 
Ketoprofen 2.07 3.26 2.28 4.92 3.93 2.39 
Naproxen 3.45 4.76 1.55 6.58 7.65 2.69 
The repeatability and intermediate precision results for the developed SPE/HPLC-
DAD methodology ranged from 0.25 to 4.76% and 0.43 to 9.27%, respectively. As expected, 
the intermediate precision present higher mean values than the repeatability since some of 
the operating conditions may change, such as small variations in the chromatographic 
column pressure, mobile phase proportions, sample temperature and others. 
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However, the obtained results were acceptable given that other published works use 
to consider that precise analytical methodologies present 20% as a maximum CV value in 
repeatability and intermediate precision studies [67, 70, 78]. 
It is possible to compare these results with the precision studies performed for other 
similar methodologies (SPE/HPLC-DAD). For acetylsalicylic acid, the calculated results for 
repeatability were better than the reported values, 22.3 and 3.8%, and the intermediate 
precision is between the 20.3 and 3.8% values [24, 88]. Regarding to diclofenac, the 
achieved precision parameters were slightly better than those from other works, 2.9, 2.6 and 
1.9% for repeatability and 3.5, 4.4 and 1.25% for intermediate precision [24, 67, 88]. 
Comparing ibuprofen results, the obtained values were better than the ones from literature, 
3.5, 16.7 and 3.9% for repeatability and 9.7, 8.8 and 4.4% for intermediate precision [24, 67, 
88]. The ketoprofen results for repeatability were similar to the 2.3% referred in reference 
[91] and much better than the 11.3% for intermediate precision from the same work. Both 
repeatability and intermediate precision results for naproxen in reference [91] were equal to 
14.3%, a higher value than the calculated ones in this work for the same analyte. 
4.1.6 Solid phase extraction operating conditions 
Firstly, the individual standard solutions were extracted, and then, the mixture with 
the five NSAIDs was also extracted. This practice was implemented in order to compare the 
recovery values for the compounds individually and in the mixture, consequently, it would 
be possible to verify if the adsorbent would present more selectivity for one individual 
compound when in the presence of the others. Nevertheless, the recovery value parameter 
was calculated using the mixture with the five compounds, since the real samples are 
mixtures as well. 
4.1.6.1 Individual extractions 
During the individual extractions, it was noticed that the loading and washing wastes 
did not carry the analyte. This means that the analyte was kept in the adsorbent and the most 
important steps are the elution and loading. For this reason, the flow-rates for these two 
stages should be lower. Table 17 shows the flow-rates for each step in the individual 
extractions and their recovery values. These experimental recovery values were calculated 
using equation (15) and (16). 
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Table 17. Experimental recovery and flow-rate values for the individual NSAIDs extractions. 





Conditioning 1 0.29 0.40 0.20 0.34 0.27 
Conditioning 2 0.41 0.32 0.51 0.54 0.47 
Loading 0.52 0.50 0.53 0.37 0.46 
Washing 1.00 1.23 1.46 0.79 1.02 
Elution 0.30 0.25 0.27 0.16 0.15 
Recovery (% c/c) 111.38 113.44 111.78 106.46 128.63 
Recovery (% m/m) 89.10 90.75 89.42 85.17 102.90 
After these studies, it was decided that the flow-rates for the loading and elution 
stages should be around 0.5 and 0.2 mL/min, respectively, to ensure higher recovery results 
with a reasonable flow-rate that could be manually controlled.  
4.1.6.2 SPE extractions of NSAID mixture 
The extraction procedure was performed in triplicate with the conditions that were 
selected based on the individual extraction studies. Table 18 presents the experimental flow-




Table 18. SPE extraction recoveries (based in concentration and mass) and flow-rate values for 
NSAIDs mixture extractions. 





Conditioning 1 0.25 0.20 0.20 0.22 0.02 10.88 
Conditioning 2 0.54 0.55 0.45 0.51 0.04 8.76 
Loading 0.50 0.54 0.56 0.53 0.02 4.68 
Washing 0.84 0.79 0.97 0.87 0.08 8.75 
Elution 0.17 0.19 0.18 0.18 0.01 4.54 
Recovery 
(% c/c) 
Ketoprofen 122.47 109.31 123.08 118.29 6.35 5.37 
Naproxen 122.95 110.37 129.43 120.92 7.91 6.54 
Diclofenac 110.23 114.59 122.32 115.71 5.00 4.32 
Ibuprofen 117.47 122.06 132.83 124.12 6.44 5.19 
Acetylsalicylic acid 118.43 102.55 121.94 114.31 8.44 7.38 
Recovery 
(% m/m) 
Ketoprofen 97.98 87.45 98.46 94.63 5.08 5.37 
Naproxen 98.36 88.30 103.55 96.74 6.33 6.54 
Diclofenac 88.18 91.70 97.85 92.58 4.00 4.32 
Ibuprofen 93.98 97.64 106.26 99.29 5.15 5.18 
Acetylsalicylic acid 94.74 82.04 97.55 91.44 6.75 7.38 
Since the available SPE equipment does not allow the direct control of the flow-rate, 
it was not simple to obtain the exact value stipulated for the method. The flow-rate control 
was done by monitoring of emptying time of the cartridge. This is the reason why the 
average, the standard deviation and the variation coefficient of the measured flow-rates were 
also calculated. Despite this, the flow-rates for the most important steps, loading and elution, 
were satisfactory, as it can be observed by their coefficients of variations below 5%. 
In addition, it was concluded that the selected adsorbent, Chromabond HLB, was 
appropriated for these compounds, because it was not shown a major interaction for one 
NSAID in relation with the others. It can be also observed that the mass basis recoveries 
range between 91.44% for acetylsalicylic acid and 99.29% for ibuprofen. These values are 
in agreement with the higher recovery values referred in literature. Some published studies 
that analyzed the same class of pharmaceutical drugs, using the Chromabond HLB adsorbent 
or similar products of other brands but with the same solid adsorbent, such as Oasis HLB or 
Strata X, refer most of the recovery values above 80% [75, 77, 88, 89]. 
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4.2  Implementation of the developed methodology 
SPE/HPLC-DAD analysis of a blank sample  
During the HPLC studies for mobile phase selection, it was noticed that between 1 
and 2 minutes, there is a normal change in the baseline of the chromatogram when the 
injected samples were prepared in methanol. This variation in the signal is related to the 
different compositions between solvent used to eluate the samples and the solvents, 
acetonitrile and water, used in mobile phase. This variation in the baseline is almost 
imperceptible when the samples have high concentrations, however it can hamper the 
analysis for very small concentrations. For this reason, it was decided to do a blank analysis 
with only methanol and analyze it in the HPLC system for all the wavelengths selected for 
the NSAID quantification. In Figure 21 are presented the chromatograms obtained for 
methanol with the four wavelengths. 
  
Figure 21. 21a: HPLC-DAD chromatograms obtained for blank analysis (pure 
methanol) using the four wavelengths (219, 224, 254 and 275 nm) and 21b: zoom of the most 
important zone. 
The presented chromatogram shows some peaks between 1 and 1.5 minutes related 
with some impurities present in acetonitrile, water and trifluoracetic acid. Between 1.5 and 
2 minutes, approximately, it can be observed a negative peak, for all the four wavelengths, 
due to methanol, and a peak at 2.5 minutes for both 219 nm and 224 nm wavelengths. 
Acetylsalicylic acid is the only compound that could be affected (2.1 min and 224 nm), 





SPE/HPLC-DAD analysis of the six samples 
As referred before, six samples were collected from different sources and locations 
in the Bragança region. The obtained chromatograms using the developed methodology 
(HPLC-DAD after SPE) are presented in Figures 20 to 26. 
  
Figure 22. 22a: HPLC-DAD chromatograms obtained for S1 using the four wavelengths 
(219, 224, 254 and 275 nm) and 22b: zoom for the most important zone. 
S1 is a sample of tap water collected from the municipal water distribution system. 
The obtained HPLC-DAD chromatogram, presented in Figure 22, shows at 2.526 min the 
methanol peak and at 3.668 min a very small peak, although, this retention time is not related 
with none of the five studied NSAID. 
S2 is a sample of tap water collected from the groundwater that supplies the 
Polytechnic Institute of Bragança (IPB). The obtained HPLC-DAD chromatograms are 






Figure 23. 23a: HPLC-DAD chromatograms obtained for S2 using the four wavelengths 
(219, 224, 254 and 275 nm) and 23b: zoom for the most important zone. 
The four chromatograms for S2, shows for the 254 nm a small signal, exactly in the 
same retention time of ketoprofen. 
S3 is a sample of surface water collected from River A, location 1, in the section that 
crosses part of IPB campus. The obtained HPLC-DAD chromatograms are presented in 
Figure 24. 
  
Figure 24. 24a: HPLC-DAD chromatograms obtained for S3 using the four wavelengths 
(219, 224, 254 and 275 nm) and 24b: zoom for the most important zone. 
The analyzes of S3 presented in the four obtained chromatograms shows one peak at 
2.519 min due to the methanol, and also presents two new signals at 2.140 and 2.830 min 
for 224 nm wavelength, corresponding to acetylsalicylic acid and naproxen, respectively. 
Besides, in 254 nm curve, there is a ketoprofen signal at 2.741 min. Another compound is 
clearly noticeable at 4.385 min using the two lowest wavelengths of 219 and 224 nm but is 
not related with any of the five studied NSAIDs. 
S4 is a sample of surface water collected from River A, location 2, at the “Polis” 






Figure 25. 25a: HPLC-DAD chromatograms obtained for S4 using the four wavelengths 
(219, 224, 254 and 275 nm) and 25b: zoom for the most important zone. 
The S4 obtained chromatograms reveal a new compound, responding using 219 and 
224 nm with a retention time of 3.589 min, so it cannot be identified as one of the five 
NSAID compounds of this study. 
S5 is a samples of surface water collected from River B. The obtained HPLC-DAD 
chromatograms are presented in Figure 26. 
  
Figure 26. 26a: HPLC-DAD chromatograms obtained for S5 using the four wavelengths 
(219, 224, 254 and 275 nm) and 26b: zoom for the most important zone. 
 
The analysis of the results obtained for S5 shows at 2.010 and 2.219 min two small 
compounds that cannot be identified as the studied five NSAID. 
The last collected sample S6 is a pool water sample from Bragança municipal sports 






Figure 27. 27a: HPLC-DAD chromatograms obtained for S6 using the four wavelengths 
(219, 224, 254 and 275 nm) and 27b: zoom for the most important zone. 
The pool water S6 sample analysis, shown in Figure 27, presents more peaks than 
the other samples. But most of them are in the beginning of the graph and they do not 
interfere in the analytes’ retention times. It can be observed a small peak, at 2.155 minutes 
for 224 nm, which identifies acetylsalicylic acid. 
A summary of the obtained average concentration, resulting from the triplicate 
analysis of the contaminated samples is presented in Table 19. The presented concentrations 
were obtained with the HPLC-DAD linear regression parameters and SPE recovery obtained 
for each compound.  
Table 19. Calculated concentration based on linear regression and recovery values for the five 
NSAID and for the contaminated samples. 
Sample Compound Concentration (ppb) 
S2 Ketoprofen <LOQ 
S3 
Acetylsalicylic acid <LOD 
Ketoprofen 11.230 ± 0.767 
Naproxen <LOQ 
S6 Acetylsalicylic acid <LOD 
From the five peaks that were detected and integrated in the samples, only one can 
be quantified since it is the only concentration above the limit of quantification. Ketoprofen 
found in S3 corresponds to a concentration of 11.230 ppb. Despite not being possible to 
quantify the other detected NSAID compounds, it is allowed to say that S2 and S3 were 
contaminated with ketoprofen and naproxen, respectively, since the concentrations for these 




Other published works reported the water contamination by ketoprofen. It is known 
that the average concentration for a same analyte may variate in different matrices and 
regions due to the amount of the consumption of this drug and the contamination sources. 
The works that analyzed and found ketoprofen in surface water samples presented results 
ranging from 0.04 to 2.00 ppb, with an average concentration of 0.55 ppb, which is lower 
than the calculated value from this work [74, 76, 89, 90]. The authors who quantified 
ketoprofen in wastewater treatment plants divided the samples into influent and effluent 
samples. The obtained concentration in influent samples ranged from 1.7 to 260 ppb and 
presented an average value of 57.38 ppb. Regarding to the wastewater treatment plant’s 
effluent samples, the values ranged from 1.2 to 160 ppb, with an average concentration of 
37.74 ppm. Both of these values were higher than the found for ketoprofen in surface water 
in this work. 
Besides that, it is noticeable that S1 and S4 showed the presence of compounds at 
3.668 and 3.589 min (for 219 nm) and S3 at 4.385 min (for 219 nm and 224 nm), which were 





























The aims of this work were to develop and to validate an experimental methodology 
to identify and quantify non-steroidal anti-inflammatory drugs. Five compounds belonging 
to this class of pharmaceutical drugs (acetylsalicylic acid, diclofenac, ibuprofen, ketoprofen 
and naproxen) were selected to develop and validate the experimental methodology in real 
samples from different hydric media of the Bragança region. 
From a careful review of the state of the art in this field, several extraction and 
quantitative analysis methods were found adequate. Taking into account the instrumental 
equipment available inside the group and the costs associated with the use of other more 
sophisticated technologies, it was decided to develop the analytical methodology using solid 
phase extraction followed by high performance liquid chromatography with photo diode 
array detector. The development of the analytical methodology involved the selection of an 
appropriate adsorbent for the solid phase extraction and the optimization of the flow-rate for 
each one of the four steps needed for SPE. Besides that, it was necessary to optimize some 
of the operating conditions of HPLC-DAD analysis, such as the mobile phase composition, 
pH, and flow-rate, as well as the DAD wavelength to be set for each analyte detection and 
quantification. 
The initial set of compounds comprised ten pharmaceutical drugs from different 
classes. After several preliminary experimental measurements, it was decided that would be 
better to develop two different methods: one for the low pKa compounds, which cover the 
non-steroidal anti-inflammatory drugs, and another method for the compounds with higher 
pKa. This work focused on the acid compounds, while the other method is being developed 
by other member of this research group. 
The developed SPE/HPLC-DAD experimental methodology is based in a first SPE 
extraction using the Chromabond® HLB adsorbent with different solvents and flow-rates 
from 0.2 to 0.9 mL/min for each one of the four SPE steps. The SPE extraction applied for 
the mixture of the five studied NSAID led to mass recovery values above 91%, with 
coefficients of variation from 4% to 7%, values that are similar or even higher than some 
others found in literature.  
The second stage of the methodology is based in HPLC-DAD analysis of the eluted 
samples, collected in the last step of SPE. The HPLC method was developed under reversed 
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phase mode, using a non-polar C18 stationary phase and a polar 
acetonitrile:water:trifluoracetic acid (60:40:0.01 (%v:v:v)) mobile phase composition. 
Taking advantage of diode array detector capabilities, four wavelengths were set in 
real time analysis in order to promote the selectivity of the five NSAID compounds since 
each one of them presents better detector response in different wavelengths. The selected 
wavelengths were 219 nm for ibuprofen, 224 nm for acetylsalicylic acid and naproxen, 254 
nm for ketoprofen and 275 nm for diclofenac. 
The statistical parameters for the calibration curves were obtained for a confidence 
level of 95%. The linearity of the five calibration curves was confirmed since the obtained 
determination coefficients values are in the range between 0.9876 for naproxen and 0.9999 
for ibuprofen. The obtained limits of quantification are in the range between 7.5 ppb for 
ketoprofen and 246.7 ppb for acetylsalicylic acid. The preliminary HPLC measurements 
with ketoprofen standard solutions using different pH values showed that lower pH values 
increase chromatographic signals. This fact can suggest that the use of a chromatographic 
column that allows to work with lower pH values could improve the results obtained for the 
limits of detection and quantification. 
After the development of SPE/HPLC-DAD methodology, the method was 
implemented analysing six real aqueous samples of the Bragança region. The samples were 
collected in different locations, including surface water, tap water, groundwater and pool 
water. From the six samples analysed, three of them were contaminated with one or more 
NSAID from the set of 5 compounds studied. Nevertheless, only ketoprofen was identified 
and quantified in S3, collected from the surface water of river A, inside IPB campus. The 
measured concentration of ketoprofen was 11.230 ± 0.767 ppb, a high value when compared 
with values referred in other published works.  
S3 was also contaminated with naproxen, but it was not possible to quantify this 
compound. S2, collected from the groundwater that supplies the IPB campus, was also 
contaminated with ketoprofen. 
As suggestions for future works, it would be interesting to improve this experimental 
methodology using a different HPLC adsorbent that can tolerate more extreme pH values, 
in order to verify if the LOD and LOQ values would be enhanced. Another option is to use 
a mobile phase with pure methanol, since this solvent is employed for the SPE elution step 
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and therefore the baseline resolution could be improved for the first 3 minutes of the HPLC 
analysis. 
Besides that, other extraction procedures can be evaluated, changing the SPE 
adsorbent, trying different solvents or using solid phase micro extraction (SPME). It also 
could be studied the use of more sophisticated analytical methods such as the HPLC coupled 
with mass spectrometry (LC-MS) or with tandem mass spectrometry (LC-MS/MS). It can 
be also considered other instrumental methods such UV-Vis, Gas chromatography coupled 
with mass spectrometry, such as GC-MS or GS-MS/MS. 
The scope of the analysed compounds could be enlarged to other classes of 
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Appendix A: Absorption spectra 
  
Figure A1. Acetaminophen absorbance spectrum. 
 
  





Figure A3. Azithromycin absorbance spectrum. 
 
  
Figure A4. Caffeine absorbance spectrum. 
 
  




Figure A6. Diclofenac absorbance spectrum. 
 
  
Figure A7. Ibuprofen absorbance spectrum. 
 
  





Figure A9. Naproxen absorbance spectrum. 
 
 




Appendix B: Calibration curves data 
Ibuprofen data 
Table A 1. Ibuprofen data for the calibration curve. 
C (ppb) A1 A2 A3 ?̅? CV% 
100000 9408289 9417965 9703830 9510028 1.4 
75000 6760827 6541913 6578263 6627001 1.4 
50000 4171459 4259441 4372266 4267722 1.9 
25000 2268008 2270698 2270063 2269590 0.1 
10000 873997 879961 881060 878339 0.4 
5000 448892 446874 450199 448655 0.3 
1000 84068 83043 84431 83847 0.7 
750 58781 61054 59532 59789 1.6 
500 39890 39653 39722 39755 0.3 
250 20625 19824 20356 20268 1.6 
100 8096 7632 8256 7995 3.3 
50 4250 4146 4269 4222 1.3 
40 3309 3939 3742 3663 7.2 
30 2599 2417 2535 2517 3.0 
 


























 xi yi xi-xmed (xi-xmed)2 yi-ymed (yi-ymed)2 (xi-xmed)( yi-ymed) 
 30 2517 -131.67 17336.1111 -10553 1.11E+08 1.39E+06 
 40 3663 -121.67 14802.7778 -9407 8.85E+07 1.14E+06 
 50 4222 -111.67 12469.4444 -8848 7.83E+07 9.88E+05 
 100 7995 -61.67 3802.7778 -5075 2.58E+07 3.13E+05 
 250 20268 88.33 7802.7778 7198 5.18E+07 6.36E+05 
 500 39755 338.33 114469.4444 26685 7.12E+08 9.03E+06 
Total 970 78420 0.00 170683.3333 0 1.07E+09 1.35E+07 
  
       
 xi yi x2 yi* yi-yi* (yi-yi*)2 Outlier 
 30.00 2517 900.0 2657 140 1.95E+04 0.71 
 40.00 3663 1600.0 3447 216 4.66E+04 1.09 
 50.00 4222 2500.0 4238 17 2.78E+02 0.08 
 100.00 7995 10000.0 8193 198 3.93E+04 1.00 
 250.00 20268 62500.0 20056 212 4.50E+04 1.07 
 500.00 39755 250000.0 39829 74 5.42E+03 0.37 
Total 970 78420 327500 78420 856 1.56E+05 - 
 
Sy/x 198  
IC 
a 310.09 
Sb 0.48  b 1.33 
Sa 112     
      
a 284 ± 310   





Acetylsalicylic acid data 
Table A 3. Ibuprofen data for the calibration curve. 
C (ppb) A1 A2 A3 ?̅? CV% 
100000 2828605 2910756 2809693 2849685 1.5 
75000 1992982 1986558 2001609 1993716 0.3 
50000 1222264 1284938 1297224 1268142 2.6 
25000 658732 652427 649510 653556 0.6 
10000 262511 288325 310654 287163 6.9 
5000 114416 109042 104635 109364 3.7 
1000 21691 20981 21949 21540 1.9 
750 13796 14988 13964 14249 3.7 
500 10921 10345 10482 10583 2.3 
250 7106 6901 7299 7102 2.3 
100 3144 3411 2876 3144 6.9 
50 2631 2516 2556 2568 1.9 
40 1289 1336 1277 1301 2.0 
 





























 xi yi xi-xmed (xi-xmed)2 yi-ymed (yi-ymed)2 (xi-xmed)( yi-ymed) 
 40.00 1301 -921.25 8.49E+05 -19930 3.97E+08 1.84E+07 
 50.00 2568 -911.25 8.30E+05 -18663 3.48E+08 1.70E+07 
 100.00 3144 -861.25 7.42E+05 -18087 3.27E+08 1.56E+07 
 250.00 7102 -711.25 5.06E+05 -14129 2.00E+08 1.00E+07 
 500.00 10583 -461.25 2.13E+05 -10648 1.13E+08 4.91E+06 
 750.00 14249 -211.25 4.46E+04 -6982 4.88E+07 1.48E+06 
 1000.00 21540 38.75 1.50E+03 309 9.52E+04 1.20E+04 
 5000.00 109364 4038.75 1.63E+07 88133 7.77E+09 3.56E+08 
Total 7690 169851 0 1.95E+07 0 9.20E+09 4.23E+08 
  
       
 xi yi x2 yi* yi-yi* (yi-yi*)2 Outlier 
 40.00 1301 1.60E+03 1228 73 5.28E+03 0.06 
 50.00 2568 2.50E+03 1445 1123 1.26E+06 0.87 
 100.00 3144 1.00E+04 2531 613 3.76E+05 0.48 
 250.00 7102 6.25E+04 5788 1314 1.73E+06 1.02 
 500.00 10583 2.50E+05 11216 633 4.01E+05 0.49 
 750.00 14249 5.63E+05 16645 2396 5.74E+06 1.86 
 1000.00 21540 1.00E+06 22073 533 2.84E+05 0.41 
 5000.00 109364 2.50E+07 108925 439 1.93E+05 0.34 
Total 7690 169851 2.69E+07 169851 7123 9.98E+06 - 
 
Sy/x 1290  
IC 
a 1310.5 
Sb 0.29  b 0.71 
Sa 536     
      
a 360 ± 1311   







Table A 5. Naproxen data for the calibration curve. 
C (ppb) A1 A2 A3 ?̅? CV% 
100000 26692759 26974104 27476592 27047818 1.2 
75000 19787347 19420711 19495736 19567931 0.8 
50000 12614911 12839374 13149833 12868039 1.7 
25000 6994468 6962072 6977961 6978167 0.2 
10000 2720206 2725576 2743295 2729692 0.4 
5000 1397153 1402288 1400894 1400112 0.2 
1000 258156 261249 261839 260415 0.6 
750 174623 193000 180513 182712 4.2 
500 124409 123236 124586 124077 0.5 
250 61280 59730 59133 60048 1.5 
100 19994 19132 20414 19847 2.7 
50 9895 10277 10109 10094 1.5 
40 6842 6974 7621 7146 4.8 
30 5341 5354 5748 5481 3.4 
20 4002 4076 4142 4073 1.4 
10 1319 1523 1628 1490 8.6 
5 977 933 919 943 2.6 
 


























 xi yi xi-xmed (xi-xmed)2 yi-ymed (yi-ymed)2 (xi-xmed)( yi-ymed) 
 5.00 943 -20.83 4.34E+02 -3928 1.54E+07 8.18E+04 
 10.00 1490 -15.83 2.51E+02 -3381 1.14E+07 5.35E+04 
 20.00 4073 -5.83 3.40E+01 -798 6.36E+05 4.65E+03 
 30.00 5481 4.17 1.74E+01 610 3.72E+05 2.54E+03 
 40.00 7146 14.17 2.01E+02 2275 5.17E+06 3.22E+04 
 50.00 10094 24.17 5.84E+02 5223 2.73E+07 1.26E+05 
Total 155 29226.66667 0 1.52E+03 0 6.03E+07 3.01E+05 
  
       
 xi yi x2 yi* yi-yi* (yi-yi*)2 Outlier 
 5.00 943 2.50E+01 748 195 3.81E+04 0.45 
 10.00 1490 1.00E+02 1737 247 6.12E+04 0.57 
 20.00 4073 4.00E+02 3717 357 1.27E+05 0.83 
 30.00 5481 9.00E+02 5696 215 4.61E+04 0.50 
 40.00 7146 1.60E+03 7675 529 2.80E+05 1.23 
 50.00 10094 2.50E+03 9654 440 1.93E+05 1.02 
Total 155 29227 5.53E+03 29227 1983 7.46E+05 - 
 
Sy/x 432  
IC 
a 933.01 
Sb 11.07  b 30.75 
Sa 336.05     
      
a -242 ± 933   






Table A 7. Ketoprofen data for the calibration curve. 
C (ppb) A1 A2 A3 ?̅? CV% 
100000 8475609 8547683 8754666 8592653 1.4 
75000 6051785 5946034 5963888 5987236 0.8 
50000 3784701 3825845 3916112 3842219 1.4 
25000 2063372 2047769 2044084 2051742 0.4 
10000 790090 769753 799352 786398 1.6 
5000 407470 408140 406871 407494 0.1 
1000 75106 74771 75314 75064 0.3 
750 52724 53223 51879 52609 1.1 
500 34692 34430 34392 34505 0.4 
250 18038 17517 17780 17778 1.2 
100 6375 6598 6600 6524 1.6 
50 3412 3608 3517 3512 2.3 
40 2709 2566 2776 2684 3.3 
30 2096 2077 2178 2117 2.1 
20 1459 1321 1548 1443 6.5 
10 696 624 594 638 6.7 
5 265 308 299 291 6.4 
 


























 xi yi xi-xmed (xi-xmed)2 yi-ymed (yi-ymed)2 (xi-xmed)( yi-ymed) 
 5.00 291 -20.83 4.34E+02 -1490 2.22E+06 3.10E+04 
 10.00 638 -15.83 2.51E+02 -1143 1.31E+06 1.81E+04 
 20.00 1443 -5.83 3.40E+01 -338 1.14E+05 1.97E+03 
 30.00 2117 4.17 1.74E+01 336 1.13E+05 1.40E+03 
 40.00 2684 14.17 2.01E+02 903 8.15E+05 1.28E+04 
 50.00 3512 24.17 5.84E+02 1732 3.00E+06 4.18E+04 
Total 155.00 10685 0 1.52E+03 0 7.57E+06 1.07E+05 
  
       
 xi yi x2 yi* yi-yi* (yi-yi*)2 Outlier 
 5.00 291 2.50E+01 313 22 4.88E+02 0.33 
 10.00 638 1.00E+02 665 27 7.47E+02 0.40 
 20.00 1443 4.00E+02 1370 73 5.31E+03 1.08 
 30.00 2117 9.00E+02 2074 43 1.82E+03 0.63 
 40.00 2684 1.60E+03 2779 95 9.05E+03 1.41 
 50.00 3512 2.50E+03 3483 29 8.43E+02 0.43 
Total 155 10685 5.53E+03 10685 289 1.83E+04 - 
 
Sy/x 68  
IC 
a 145.96 
Sb 1.73  b 4.81 
Sa 52.57     
      
a -39 ± 146   






Table A 9. Diclofenac data for the calibration curve. 
C (ppb) A1 A2 A3 ?̅? CV% 
100000 3617815 3651070 3714509 3661131 1.1 
75000 2581630 2517210 2538916 2545919 1.1 
50000 1609478 1621581 1673184 1634748 1.7 
25000 873182 870295 873512 872330 0.2 
10000 337150 337989 337699 337613 0.1 
5000 172127 172677 171385 172063 0.3 
1000 30794 31795 31722 31437 1.4 
750 21750 22749 22333 22277 1.8 
500 14431 14390 14698 14506 0.9 
250 7847 7757 7481 7695 2.0 
100 2483 2585 2563 2544 1.7 
 



















Average 1266.67 41753.72 
 
 xi yi xi-xmed (xi-xmed)2 yi-ymed (yi-ymed)2 (xi-xmed)( yi-ymed) 
 100.00 2544 -1166.67 1.36E+06 -39210 1.54E+09 4.57E+07 
 250.00 7695 -1016.67 1.03E+06 -34059 1.16E+09 3.46E+07 
 500.00 14506 -766.67 5.88E+05 -27247 7.42E+08 2.09E+07 
 750.00 22277 -516.67 2.67E+05 -19476 3.79E+08 1.01E+07 
 1000.00 31437 -266.67 7.11E+04 -10317 1.06E+08 2.75E+06 
 5000.00 172063 3733.33 1.39E+07 130309 1.70E+10 4.86E+08 





      
 xi yi x2 yi* yi-yi* (yi-yi*)2 Outlier 
 
88 
 100.00 2544 1.00E+04 1156 1388 1.93E+06 1.02 
 250.00 7695 6.25E+04 6375 1320 1.74E+06 0.97 
 500.00 14506 2.50E+05 15075 569 3.23E+05 0.42 
 750.00 22277 5.63E+05 23775 1497 2.24E+06 1.10 
 1000.00 31437 1.00E+06 32474 1037 1.08E+06 0.76 
 5000.00 172063 2.50E+07 171668 395 1.56E+05 0.29 
Total 7600 250522 2.69E+07 250522 6206 7.47E+06 - 
 
Sy/x 1366  
IC 
a 1932.67 
Sb 0.33  b 0.91 
Sa 696.09     
      
a -2324 ± 1933   
b 35 ± 1   
 
 
